Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes
- 532 Downloads
Herpes simplex virus type 1 (HSV-1) is the most common pathogenic cause of sporadic acute encephalitis and it produces latent persistent infection lifelong in infected individuals. Brain inflammation is associated with activation of glial cells, which can detect pathogen-associated molecular patterns (PAMPs) through a variety of pattern-recognition receptors (PRR), including Toll-like receptors (TLRs). In this study, we evaluated the expression and activation of TLR2, TLR3, and TLR4 in HSV-1-infected astrocyte and neuronal primary cultures. Our results showed a clear induction in TLR2 and TLR4 expression in astrocytes as early as 1 h after HSV-1 infection, whereas no significant change was observed in neurons. In addition, infected astrocytes showed increased levels of interferon regulatory factors IRF3 and IRF7, interferon β (INFβ), interleukin 6 (IL6), and serum amyloid A (SAA3) transcripts, as well as phospho-IRF3 protein. These effects seemed to be dependent on viral replication since previous treatment of the cells with acyclovir resulted in low levels of TLRs expression and activation even after 4 h post-infection. These results suggest that reactivation of HSV-1 at the central nervous system (CNS) would likely induce and activate TLR2 and TLR4 receptors directly through interaction of astrocytes with the pathogen and also indirectly by endogenous ligands produced locally, such as serum amyloid protein, potentiating the neuroinflammatory response.
KeywordsHSV-1 TLRs A-SAA SAA3 Interferon
The study was supported by Fondecyt Project 11080067 and DID-UACH S-2009-40.
Conflict of interest
The authors have no conflict of interest to declare.
- 2.Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE 3(11):e3637. doi: 10.1371/journal.pone.0003637 PubMedCrossRefGoogle Scholar
- 7.Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C (2008) Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimer Dis 14(3):1–11Google Scholar
- 8.Otth C, Zambrano A, Concha M (2009) The possible link between herpes simplex virus type 1 infection and neurodegeneration. In: Maccioni RB, Perry G (eds) Current hypotheses and research Milestones in Alzheimer’s disease. Springer, New York, pp 181–188. ISBN 978-0-387-87994-9Google Scholar
- 9.Lerchundi R, Neira R, Valdivia S, Vio K, Concha MI, Zambrano A, Otth C (2011) Tau cleavage at D421 by caspase-3 is induced in neurons and astrocytes infected with Herpes Simplex Virus type 1. J Alzheimer Dis 23(3):513–520Google Scholar
- 16.Kindy MS, Yu J, Guo JT, Zhu H (1999) Apolipoprotein serum amyloid A in Alzheimer’s disease. J Alzheimer Dis 1(3):155–167Google Scholar
- 18.Zhu J, Mohan C (2010) Toll-like receptor signaling pathways-therapeutic opportunities. Mediat Inflamm. doi: 10.1155/2010/781235
- 28.Tsitoura E, Thomas J, Cuchet D, Thoinet K, Mavromara P, Epstein AL (2009) Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. J Gen Virol 90(Pt 9):2209–2220PubMedCrossRefGoogle Scholar
- 32.Rasmussen SB, Sørensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, Paludan SR (2007) Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 81(24):13315–13324PubMedCrossRefGoogle Scholar
- 36.Conde J, Gomez R, Bianco G, Scotese M, Lear P, Dieguez C, Gomez-Reino J, Lago F, Gualillo O (2011) Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 70(3):551–559Google Scholar